|Drug class||Carboxylic acids and derivatives|
|Protein binding||42% (parent drug), 3% (active metabolite)|
|Metabolism||Liver, to oseltamivir carboxylate|
|Elimination half-life||1–3 hours, 6–10 hours (active metabolite)|
|Excretion||Urine (>90% as oseltamivir carboxylate), faeces|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||312.410 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, the viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.
Recommendations regarding oseltamivir are controversial as are criticisms of the recommendations. A 2014 Cochrane Review concluded that oseltamivir does not reduce hospitalizations, and that there is no evidence of reduction in complications of influenza. Two meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. They also found little evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations. However, another meta-analysis found that oseltamivir was effective for prevention of influenza at the individual and household levels.
Common side effects include vomiting, diarrhea, headache, and trouble sleeping. Other side effects may include psychiatric symptoms and seizures. In the United States it is recommended for influenza infection during pregnancy. It has been taken by a small number of pregnant women without signs of problems. Dose adjustment may be needed in those with kidney problems.
Oseltamivir was approved for medical use in the US in 1999. It was the first neuraminidase inhibitor available by mouth. It is on the World Health Organization's List of Essential Medicines but was downgraded to "complementary" status in 2017. A generic version was approved in the US in 2016. In 2019, it was the 129th most commonly prescribed medication in the United States, with more than 5 million prescriptions.
Oseltamivir is used for the prevention and treatment of influenza caused by influenza A and B viruses. It is on the World Health Organization's List of Essential Medicines. The WHO supports its use for severe illness due to confirmed or suspected influenza virus infection in critically ill people who have been hospitalized. Oseltamivir's risk-benefit ratio is controversial. In 2017, it was moved from the core to the complementary list based on its lower cost-effectiveness. The Expert Committee did not recommend the deletion of oseltamivir from the EML and EMLc, recognizing that it is the only medicine included on the Model Lists for critically ill patients with influenza and for influenza pandemic preparedness. However, the Committee noted that, since the inclusion of oseltamivir on the Model List in 2009, new evidence in seasonal and pandemic influenza has lowered earlier estimates of the magnitude of effect of oseltamivir on relevant clinical outcomes. The Committee recommended that the listing of oseltamivir be amended, moving the medicine from the core to the Complementary List, and that its use be restricted to severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients. The Expert Committee noted that WHO guidelines for pharmacological management of pandemic and seasonal influenza would be updated in 2017: unless new information is provided to support the use of oseltamivir in seasonal and pandemic outbreaks, the next Expert Committee might consider oseltamivir for deletion.
The US Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC), Public Health England and the American Academy of Pediatrics (AAP) recommend the use of oseltamivir for people who have complications or are at high risk for complications. This includes those who are hospitalized, young children, those over the age of 65, people with other significant health problems, those who are pregnant, and Indigenous peoples of the Americas among others. The Infectious Disease Society of America takes the same position as the CDC.
A systematic review of systematic reviews in PLoS One did not find evidence for benefits in people who are at risk, noting that "the trials were not designed or powered to give results regarding serious complications, hospitalization and mortality", as did a 2014 Cochrane Review. The Cochrane Review further recommended: "On the basis of the findings of this review, clinicians and healthcare policy-makers should urgently revise current recommendations for use of the neuraminidase inhibitors (NIs) for individuals with influenza." That is not utilizing NIs for prevention or treatment "Based on these findings there appears to be no evidence for patients, clinicians or policy-makers to use these drugs to prevent serious outcomes, both in annual influenza and pandemic influenza outbreaks."
The CDC, ECDC, Public Health England, Infectious Disease Society of America, the AAP, and Roche (the originator) reject the conclusions of the Cochrane Review, arguing in part that the analysis inappropriately forms conclusions about outcomes in people who are seriously ill based on results obtained primarily in healthy populations, and that the analysis inappropriately included results from people not infected with influenza. The EMA did not change its labeling of the drug in response to the Cochrane study.
A 2014 review in the New England Journal of Medicine recommended that all people admitted to intensive care units during influenza outbreaks with a diagnosis of community-acquired pneumonia receive oseltamivir until the absence of influenza infection is established by PCR testing.
A 2015 systematic review and meta-analysis found oseltamivir effective at treating the symptoms of influenza, reducing the length of hospitalization, and reducing the risk of otitis media. The same review found that oseltamivir did not significantly increase the risk of adverse events. A 2016 systematic review found that oseltamivir slightly reduced the time it takes for the symptoms of influenza to be alleviated, and that it also increased the risk of "nausea, vomiting, [and] psychiatric events in adults and vomiting in children." The decrease in duration of sickness was about 18 hours.
Otherwise healthy people
Two 2013 meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. When the analysis was restricted to people with confirmed infection, the same 2014 Cochrane Review (see above) found unclear evidence of change in the risk of complications such as pneumonia, while three other reviews found a decreased risk. Together, published studies suggest that oseltamivir reduces the duration of symptoms by 0.5–1.0 day. Any benefit of treatment must be balanced against side effects, which include psychiatric symptoms and increased rates of vomiting.
The 2014 Cochrane Collaboration review concluded that oseltamivir did not affect the need for hospitalizations, and that there is no proof of reduction of complications of influenza (such as pneumonia) because of a lack of diagnostic definitions, or reduction of the spread of the virus. There was also evidence that suggested that oseltamivir prevented some people from producing sufficient numbers of their own antibodies to fight infection. The authors recommended that guidance should be revised to take account of the evidence of small benefit and increased risk of harms.
The US Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC), the Public Health England (PHE), the Infectious Disease Society of America (IDSA), the American Academy of Pediatrics (AAP), and Roche (the originator) rejected the recommendations of the 2014 Cochrane Review to urgently change treatment guidelines and drug labels.
As of 2017[update], the CDC does not recommend to use oseltamivir generally for prevention due to concerns that widespread use will encourage resistance development. They recommend that it be considered in those at high risk, who have been exposed to influenza within 48 hours and have not received or only recently been vaccinated. They recommended it during outbreaks in long term care facilities and in those who are significantly immunosuppressed.
As of 2011[update], reviews concluded that when oseltamivir is used preventatively it decreases the risk of exposed people developing symptomatic disease. A systematic review of systematic reviews found low to moderate evidence that it decreases the risk of getting symptomatic influenza by 1 to 12% (a relative decrease of 64 to 92%). It recommended against its use in healthy, low-risk persons due to cost, the risk of resistance development, and side effects and concluded it might be useful for prevention in unvaccinated high risk persons.
Common adverse drug reactions (ADRs) associated with oseltamivir therapy (occurring in over 1 percent of people) include nausea and vomiting. In adults, oseltamivir increased the risk of nausea for which the number needed to harm was 28 and for vomiting was 22. So, for every 22 adult people on oseltamivir one experienced vomiting. In the treatment of children, oseltamivir also induced vomiting. The number needed to harm was 19. So, for every 19 children on oseltamivir one experienced vomiting. In prevention there were more headaches, kidney, and psychiatric events. Oseltamivir's effect on the heart is unclear: it may reduce cardiac symptoms, but may also induce serious arrhythmias.
Postmarketing reports include liver inflammation and elevated liver enzymes, rash, allergic reactions including anaphylaxis, toxic epidermal necrolysis, abnormal heart rhythms, seizure, confusion, aggravation of diabetes, and haemorrhagic colitis and Stevens–Johnson syndrome.
The US and EU package inserts for oseltamivir contain a warning of psychiatric effects observed in post-marketing surveillance. The frequency of these appears to be low and a causative role for oseltamivir has not been established. The 2014 Cochrane Review found a dose-response effect on psychiatric events. In trials of prevention in adults one person was harmed for every 94 treated. Neither of the two most cited published treatment trials of oseltamivir reported any drug-attributable serious adverse events.
It is pregnancy category C in the United States and category B in Australia, meaning that it has been taken by a small number of women without signs of problems and in animal studies it looks safe. Dose adjustment may be needed in those with kidney problems.
Mechanism of action
Oseltamivir is a neuraminidase inhibitor, a competitive inhibitor of influenza's neuraminidase enzyme. The enzyme cleaves the sialic acid which is found on glycoproteins on the surface of human cells that helps new virions to exit the cell. Thus oseltamivir prevents new viral particles from being released.
The vast majority of mutations conferring resistance are single amino acid residue substitutions (His274Tyr in N1) in the neuraminidase enzyme. A 2011 meta-analysis of 15 studies found a pooled incidence rate for oseltamivir resistance of 2.6%. Subgroup analyses detected higher rates among influenza A patients, especially the H1N1 subtype. It was found that a substantial number of patients might become oseltamivir-resistant as a result of oseltamivir use, and that oseltamivir resistance might be significantly associated with pneumonia. In severely immunocompromised patients there were reports of prolonged shedding of oseltamivir- (or zanamivir)-resistant virus, even after oseltamivir treatment was stopped.
H1N1 flu or "Swine flu"
The CDC found sporadic oseltamivir-resistant 2009 H1N1 virus infections had been identified, including with rare episodes of limited transmission, but the public health impact had been limited. Those sporadic cases of resistance were found in immunosuppressed patients during oseltamivir treatment and persons who developed illness while receiving oseltamivir chemoprophylaxis.
During 2011, a new influenza A(H1N1)2009 variant with mildly reduced oseltamivir (and zanamivir) sensitivity was detected in more than 10% of community specimens in Singapore and more than 30% of samples from northern Australia.
While there is concern that antiviral resistance may develop in people with haematologic malignancies due to their inability to reduce viral loads and several surveillance studies found oseltamivir-resistant pH1N1 after administration of oseltamivir in those people, as of November 2013[update], widespread transmission of oseltamivir-resistant pH1N1 has not occurred.
During the 2007–08 flu season, the US CDC found 10.9% of H1N1 samples (n=1,020) to be resistant. In the 2008–09 season, the proportion of resistant H1N1 increased to 99.4%, while no other seasonal strains (H3N2, B) showed resistance.
From 2009 to 2014, oseltamivir resistance was very low in seasonal flu. In the 2010–11 flu season, 99.1% of H1N1, 99.8% of H3N, and 100% of Influenza B remained oseltamivir susceptible in the US. In January 2012, the US and European CDCs reported all seasonal flu samples tested since October 2011 to be oseltamivir susceptible. In the 2013–14 season only 1% of 2009 H1N1 viruses showed oseltamivir resistance. No other influenza viruses were resistant to oseltamivir.
Three studies have found resistance in 0%, 3.3%, and 18% of subjects. In the study with the 18% resistance rate, the subjects were children, many of whom had not been previously exposed to influenza and therefore had a weakened immune response; the results suggest that higher and earlier dosing may be necessary in such populations.
In 2007, Japanese investigators detected neuraminidase-resistant influenza B virus strains in individuals not treated with these drugs. The prevalence was 1.7%. According to the CDC, As of 2019[update], transmission of oseltamivir-resistant influenza B virus strains—from persons treated with the drug—is rare.
H5N1 Avian influenza "Bird flu"
As of 2013[update], H274Y and N294S mutations that confer resistance to oseltamivir have been identified in a few H5N1 isolates from infected patients treated with oseltamivir, and have emerged spontaneously in Egypt.
H7N9 Avian influenza
Its oral bioavailability is over 80% and is extensively metabolised to its active form upon first-pass through the liver. It has a volume of distribution of 23–26 litres. Its half-life is about 1–3 hours and its active carboxylate metabolite has a half-life of 6–10 hours. More than 90% of the oral dose is eliminated in the urine as the active metabolite.
Oseltamivir was discovered by scientists at Gilead Sciences using shikimic acid as a starting point for synthesis; shikimic acid was originally available only as an extract of Chinese star anise; but by 2006, 30% of the supply was manufactured recombinantly in E. coli. Gilead exclusively licensed their relevant patents to Roche in 1996. The drug's patent has not been protected in Thailand, the Philippines, Indonesia, and several other countries.
In 1999, the FDA approved oseltamivir phosphate for the treatment of influenza in adults based on two double-blinded, randomized, placebo-controlled clinical trials. In June 2002, the European Medicines Agency (EMA) approved oseltamivir phosphate for prophylaxis and treatment of influenza. In 2003, a pooled analysis of ten randomised clinical trials concluded that oseltamivir reduced the risk of lower respiratory tract infections resulting in antibiotic use and hospital admissions in adults.
Oseltamivir (as Tamiflu) was widely used during the H5N1 avian influenza epidemic in Southeast Asia in 2005.[medical citation needed] In response to the epidemic, various governments – including those of the United Kingdom, Canada, Israel, United States, and Australia – stockpiled quantities of oseltamivir in preparation for a possible pandemic and there were worldwide shortages of the drug, driven by the high demand for stockpiling. In November 2005, US President George W. Bush requested that Congress fund US$1 billion for the production and stockpile of oseltamivir, after Congress had already approved $1.8 billion for military use of the drug. Defense Secretary Donald Rumsfeld, who was a past chairman of Gilead Sciences, recused himself from all government decisions regarding the drug.
In 2006, a Cochrane Review (since withdrawn) raised controversy by concluding that oseltamivir should not be used during routine seasonal influenza because of its low effectiveness.
In December 2008, the Indian drug company Cipla won a case in India's court system allowing it to manufacture a cheaper generic version of Tamiflu, called Antiflu. In May 2009, Cipla won approval from the World Health Organization (WHO) certifying that its drug Antiflu was as effective as Tamiflu, and Antiflu is included in the WHO list of prequalified medicinal products.
In 2009, a new A/H1N1 influenza virus was discovered to be spreading in North America. In June 2009, the WHO declared the A/H1N1 influenza a pandemic. The National Institute for Health and Care Excellence (NICE), the CDC, the WHO, and the ECDC maintained their recommendation to use oseltamivir.
From 2010 to 2012, Cochrane requested Roche's full clinical study reports of their trials, which they did not provide. In 2011, a freedom of information request to the European Medicines Agency (EMA) provided Cochrane with reports from 16 Roche oseltamivir trials. In 2012, the Cochrane team published an interim review based on those reports. In 2013, Roche released 74 full clinical study reports of oseltamivir trials after GSK released the data on zanamivir studies. In 2014, Cochrane published an updated review based solely on full clinical study reports and regulatory documents. In 2016, Roche's oseltamivir patents began to expire.
There have been[when?] reports of oseltamivir reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacterial colonization and toxin production.
This article needs to be updated.(October 2021)
- Amantadine and rimantadine – M2 inhibitors, for influenza treatment
- Baloxavir marboxil, an endonuclease inhibitor, for influenza treatment
- "Oseltamivir (Tamiflu) Use During Pregnancy". Drugs.com. Archived from the original on 9 September 2017. Retrieved 16 January 2017.
- Davies BE (April 2010). "Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations". The Journal of Antimicrobial Chemotherapy. 65 (Suppl 2): ii5–ii10. doi:10.1093/jac/dkq015. PMC 2835511. PMID 20215135.
- "Oseltamivir Phosphate Monograph for Professionals". The American Society of Health-System Pharmacists. Archived from the original on 13 May 2016. Retrieved 8 January 2017.
- "CDC Recommendations for Influenza Antiviral Medications Remain Unchanged". U.S. Centers for Disease Control and Prevention (CDC). 10 April 2014. Archived from the original on 18 January 2017. Retrieved 16 January 2017.
- European Centre for Disease Prevention and Control (2 June 2014). "New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published". Archived from the original on 2014-11-02.
- "Amantadine, oseltamivir and zanamivir for the treatment of influenza". National Institute for Health and Care Excellence (NICE). 25 February 2009. Archived from the original on 18 January 2017. Retrieved 16 January 2017.
- "IDSA Continues to Recommend Antivirals for Influenza". Archived from the original on 24 April 2014. Retrieved 24 April 2014.
- Brownlee S (19 February 2013). "Tamiflu: Myth and Misconception". The Atlantic. Archived from the original on 29 December 2014. Retrieved 7 December 2014.
- Butler D (April 2014). "Tamiflu report comes under fire". Nature. 508 (7497): 439–40. Bibcode:2014Natur.508..439B. doi:10.1038/508439a. PMID 24759392.
- Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013). Jefferson T (ed.). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLOS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.
- Ebell MH, Call M, Shinholser J (April 2013). "Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials". Family Practice. 30 (2): 125–33. doi:10.1093/fampra/cms059. PMID 22997224.
- Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS (9 December 2014). "Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies". PLOS ONE. 9 (12): e113633. Bibcode:2014PLoSO...9k3633O. doi:10.1371/journal.pone.0113633. PMC 4260958. PMID 25490762.
- Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (April 2012). Harnden A (ed.). "Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)". The Cochrane Database of Systematic Reviews. 4 (4): CD002744. doi:10.1002/14651858.CD002744.pub4. PMC 6599832. PMID 22513907.
- Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ (April 2014). "Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments". BMJ. 348: g2545. doi:10.1136/bmj.g2545. PMC 3981975. PMID 24811411.
- Agrawal R, Rewatkar PV, Kokil GR, Verma A, Kalra A (July 2010). "Oseltamivir: a first line defense against swine flu". Medicinal Chemistry. 6 (4): 247–251. doi:10.2174/1573406411006040247. PMID 20843284.
- World Health Organization (2017). The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/259481. ISBN 9789241210157. WHO technical report series;1006. License: CC BY-NC-SA 3.0 IGO.
- Ebell MH (July 2017). "WHO downgrades status of oseltamivir". BMJ. 358: j3266. doi:10.1136/bmj.j3266. PMID 28701339. S2CID 206916214.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "The FDA approves first generic version of widely used influenza drug, Tamiflu". U.S. Food and Drug Administration (FDA). 4 August 2016. Archived from the original on 8 August 2016. Retrieved 6 August 2016.
- "Drugs@FDA: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 9 January 2020.
- "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.
- "Oseltamivir - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.
- "Tamiflu- oseltamivir phosphate capsule Tamiflu- oseltamivir phosphate powder, for suspension". DailyMed. 15 November 2019. Retrieved 30 January 2020.
- Kmietowicz Z (June 2017). "WHO downgrades oseltamivir on drugs list after reviewing evidence". BMJ. 357: j2841. doi:10.1136/bmj.j2841. PMID 28607038. S2CID 42931361.
- "Influenza Antiviral Medications: Summary for Clinicians". U.S. Centers for Disease Control and Prevention (CDC). 3 December 2014. Archived from the original on 13 December 2014. Retrieved 9 December 2014.
- Committee On Infectious Diseases (November 2014). "Recommendations for prevention and control of influenza in children, 2014-2015". Pediatrics. 134 (5): e1503-19. doi:10.1542/peds.2014-2413. PMID 25246619.
- Public Health England (November 2014). "The use of antivirals for the treatment and prophylaxis of influenza: PHE summary of current guidance for healthcare professionals" (PDF). Archived (PDF) from the original on 2014-12-08.
- Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children". The Cochrane Database of Systematic Reviews. 4 (4): CD008965. doi:10.1002/14651858.CD008965.pub4. PMC 6464969. PMID 24718923.
- "Researchers, regulators and Roche row over stockpiled drug Tamiflu". Reuters. 9 April 2014. Archived from the original on 2015-09-24.
- Musher DM, Thorner AR (October 2014). "Community-acquired pneumonia". New England Journal of Medicine. 371 (17): 1619–28. doi:10.1056/NEJMra1312885. PMID 25337751.
- Qiu S, Shen Y, Pan H, Wang J, Zhang Q (2015). "Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials". Infectious Diseases. 47 (11): 808–19. doi:10.3109/23744235.2015.1067369. PMID 26173991. S2CID 207746253.
- Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, et al. (May 2016). "Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data". Health Technology Assessment. 20 (42): 1–242. doi:10.3310/hta20420. PMC 4904189. PMID 27246259.
- Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS (May 2018). "Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials". Clinical Infectious Diseases. 66 (10): 1492–1500. doi:10.1093/cid/cix1040. PMID 29186364.
- Holzinger F, Beck S, Dini L, Stöter C, Heintze C (May 2014). "The diagnosis and treatment of acute cough in adults". Deutsches Ärzteblatt International. 111 (20): 356–63. doi:10.3238/arztebl.2014.0356. PMC 4047603. PMID 24882627.
- Hernán MA, Lipsitch M (August 2011). "Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials". Clinical Infectious Diseases. 53 (3): 277–9. doi:10.1093/cid/cir400. PMC 3137795. PMID 21677258.
- Dobson J, Whitley RJ, Pocock S, Monto AS (May 2015). "Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials". Lancet. 385 (9979): 1729–37. doi:10.1016/S0140-6736(14)62449-1. PMID 25640810. S2CID 30589393.
- Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, et al. (September 2009). "Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 9 (9): 537–45. doi:10.1016/S1473-3099(09)70199-9. PMID 19665930.
- "Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087". 30 March 2001. Archived from the original on 2014-04-16.
- Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, Nicholson KG (January 2011). "Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review". The Journal of Infection. 62 (1): 14–25. doi:10.1016/j.jinf.2010.10.003. PMID 20950645.
- "Roche – Doing now what patients need next" (PDF). Archived from the original (PDF) on 2005-11-03.
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
- Cohen D (9 April 2014). "Oseltamivir: another case of regulatory failure?". BMJ. 348 (apr09 8): g2591. doi:10.1136/bmj.g2591. S2CID 72592926.
- "Pediatric safety update for Tamiflu" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 2007-09-27.
- Waknine Y (14 November 2006). "Tamiflu May Be Linked to Risk for Self-Injury and Delirium". Medscape. Archived from the original on 25 November 2011. Retrieved 17 May 2008.
- "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
- Thorlund K, Awad T, Boivin G, Thabane L (May 2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134. PMC 3123567. PMID 21592407.
- "Update on oseltamivir resistance to influenza H1N1 (2009) viruses" (PDF). World Health Organization (WHO). 15 December 2010. Archived (PDF) from the original on 27 January 2011. Retrieved 30 December 2010.
- "Antiviral Drug Resistance among Influenza Viruses Guidance on the Use of Influenza Antiviral Agents (Current for the 2013–14 Influenza Season)". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 13 February 2014. Retrieved 21 April 2014.
- Hurt AC (9 June 2011). "Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation". Eurosurveillance. Archived from the original on 23 April 2014.
- Downing M (November 2013). "Antiviral Therapy for Pandemic Influenza A (H1N1) Infection: Dosing, Combination Therapy, and Resistance" (PDF). National collaborating centre for infectious diseases. Archived from the original (PDF) on 2014-04-19. Retrieved 2014-04-18.
- "2007–08 U.S. Influenza Season Summary". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 2011-10-20.
- "Influenza (Flu) – Weekly Report: Influenza Summary Update Week 53, 2008-2009 Season". Archived from the original on 2011-10-20.
- "2010-2011 Influenza Season Summary". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 2012-01-25.
- "2011-2012 Influenza Season Week 51 ending December 24, 2011". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 2013-05-17.
- "Main surveillance developments in week 51/2011 (19–25 December 2011)" (PDF). European Centre for Disease Prevention and Control (ECDC). January 2012. Archived (PDF) from the original on 2012-06-10.
- "CDC Influenza Division Key Points, March 28, 2014" (PDF). U.S. Centers for Disease Control and Prevention (CDC). 28 March 2014. Archived from the original (PDF) on 2 April 2014. Retrieved 15 April 2014.
- Ward P, Small I, Smith J, Suter P, Dutkowski R (February 2005). "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic". The Journal of Antimicrobial Chemotherapy. 55 (Suppl 1): i5–i21. doi:10.1093/jac/dki018. PMID 15709056.
- Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. (April 2007). "Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors". JAMA. 297 (13): 1435–42. doi:10.1001/jama.297.13.1435. PMID 17405969.
- "Antiviral Drug Resistance among Influenza Viruses". U.S. Centers for Disease Control and Prevention (CDC). 2019-04-17. Retrieved 2020-01-29.
- McKimm-Breschkin JL (January 2013). "Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance". Influenza and Other Respiratory Viruses. 7 (Suppl 1): 25–36. doi:10.1111/irv.12047. PMC 4942987. PMID 23279894.
- Hay AJ, Hayden FG (June 2013). "Oseltamivir resistance during treatment of H7N9 infection". Lancet. 381 (9885): 2230–2. doi:10.1016/S0140-6736(13)61209-X. PMID 23809549. S2CID 39375028.
- Farina V, Brown JD (November 2006). "Tamiflu: the supply problem". Angewandte Chemie. 45 (44): 7330–4. doi:10.1002/anie.200602623. PMID 17051628.
- Rawat G, Tripathi P, Saxena RK (May 2013). "Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends". Applied Microbiology and Biotechnology. 97 (10): 4277–87. doi:10.1007/s00253-013-4840-y. PMID 23553030. S2CID 17660413.
- "Avian Flu Drugs: Patent Questions". WIPO. April 2006. Archived from the original on 2009-12-08.
- "Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 9 January 2020. Retrieved 9 January 2020.
- "OseltamivirMedical Review" (PDF). U.S. Food and Drug Administration. Archived from the original (PDF) on 2014-04-16.
- Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F (July 2003). "Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations". Archives of Internal Medicine. 163 (14): 1667–72. doi:10.1001/archinte.163.14.1667. PMID 12885681.
- Heiberg M (14 October 2005). "Oseltamivir-resistant H5N1 virus isolated from Vietnamese girl". University of Minnesota. Archived from the original on 14 December 2014. Retrieved 7 December 2014.
- Brownlee S, Lenzer J (November 2009). "Does the Vaccine Matter?". The Atlantic. Archived from the original on 2010-01-04.
- Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D (July 2006). Jefferson T (ed.). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults" (PDF). The Cochrane Database of Systematic Reviews (3): CD001265. doi:10.1002/14651858.CD001265.pub2. PMC 2790574. PMID 16855962. (Retracted, see doi:10.1002/14651858.cd001265.pub3)
- "Cipla's anti-flu drug gets nod". The Times of India. 2009-05-14. Archived from the original on 2012-10-23. Retrieved 2009-07-29.
- Jefferson T, Doshi P (April 2014). "Multisystem failure: the story of anti-influenza drugs". BMJ. 348 (apr10 14): g2263. doi:10.1136/bmj.g2263. PMID 24721793. S2CID 13490764.
- "WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010" (PDF). WHO. Archived (PDF) from the original on 2013-10-27.
- "Tamiflu campaign". BMJ. Retrieved 21 January 2020.
- Cohen, D. (April 2013). "Roche offers researchers access to all Tamiflu trials". BMJ. 346 (apr04 3): f2157. doi:10.1136/bmj.f2157. ISSN 1756-1833. PMID 23558407. S2CID 5469580.
- Savigny MR, Macintire DK (February 2010). "Use of oseltamivir in the treatment of canine parvoviral enteritis". Journal of Veterinary Emergency and Critical Care. 20 (1): 132–42. doi:10.1111/j.1476-4431.2009.00404.x. PMID 20230441.
- Macintire, Douglass K. (2006). "Treatment of Parvoviral Enteritis". Proceedings of the Western Veterinary Conference. Retrieved 2007-06-09.
- "Coronavirus COVID-19 (SARS-CoV-2)". Johns Hopkins ABX Guide. Retrieved 12 April 2020.
- Pollack A (5 November 2005). "Is Bird Flu Drug Really So Vexing? Debating the Difficulty of Tamiflu". The New York Times.
- Wong SS, Yuen KY (January 2006). "Avian influenza virus infections in humans". Chest. 129 (1): 156–68. doi:10.1378/chest.129.1.156. PMC 7094746. PMID 16424427.
- Rohloff JC, Kent KM, Postich MJ, Becker MW, Chapman HH, Kelly DE, et al. (1998). "Practical Total Synthesis of the Anti-Influenza Drug GS-4104". The Journal of Organic Chemistry. 63 (13): 4545–4550. doi:10.1021/jo980330q.
- Karpf M, Trussardi R (March 2001). "New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu)". The Journal of Organic Chemistry. 66 (6): 2044–51. doi:10.1021/jo005702l. PMID 11300898.
- Abrecht S, Harrington P, Iding H, Karpf M, Trussardi R, Wirz B, Zutter U (2004). "The Synthetic Development of the Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu): A Challenge for Synthesis & Process Research". CHIMIA International Journal for Chemistry. 58 (9): 621–629. doi:10.2533/000942904777677605.
- Yeung YY, Hong S, Corey EJ (May 2006). "A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid". Journal of the American Chemical Society. 128 (19): 6310–1. doi:10.1021/ja0616433. PMID 16683783.
- Tse N, Cederbaum S, Glaspy JA (October 1991). "Hyperammonemia following allogeneic bone marrow transplantation". American Journal of Hematology. 38 (2): 140–1. doi:10.1002/ajh.2830380213. PMID 1951305. S2CID 45068099.
- Schneider RU (April 2001). "The race to develop GS4104". NZZ Folio (in German).
- "FDA Drug Safety Communication: Important safety changes to the influenza drug Tamiflu (oseltamivir phosphate) for oral suspension". U.S. Food and Drug Administration (FDA). 31 August 2011.
|Wikimedia Commons has media related to:|